KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Income towards Parent Company: 2016-2024

Historic Income towards Parent Company for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$3.6 billion.

  • Moderna's Income towards Parent Company fell 1638.46% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 40.11%. This contributed to the annual value of -$3.6 billion for FY2024, which is 24.46% up from last year.
  • Moderna's Income towards Parent Company amounted to -$3.6 billion in FY2024, which was up 24.46% from -$4.7 billion recorded in FY2023.
  • Over the past 5 years, Moderna's Income towards Parent Company peaked at $12.2 billion during FY2021, and registered a low of -$4.7 billion during FY2023.
  • In the last 3 years, Moderna's Income towards Parent Company had a median value of -$3.6 billion in 2024 and averaged $29.0 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first spiked by 1,733.47% in 2021, then plummeted by 156.37% in 2023.
  • Moderna's Income towards Parent Company (Yearly) stood at -$747.0 million in 2020, then surged by 1,733.47% to $12.2 billion in 2021, then tumbled by 31.47% to $8.4 billion in 2022, then tumbled by 156.37% to -$4.7 billion in 2023, then grew by 24.46% to -$3.6 billion in 2024.